Results 61 to 70 of about 1,100,659 (258)

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +1 more source

Multi‐Technique Integration Identifies O‐GlcNAc Transferase in Fibroblast‐Like Synoviocytes as a Therapeutic Target for Rheumatoid Arthritis

Advanced Science, EarlyView.
AI‑guided single‑cell transcriptomics identifies OGT as a key regulator enriched in rheumatoid arthritis fibroblast‑like synoviocytes (RA‐FLSs). Inflammatory stimuli activate the OGT–SAP130 axis, which modulates the H3K27ac/H3K27me3 balance and epigenetically silences BTG2, promoting aggressive transformation of RA‑FLSs.
Duoli Xie, Jie Huang, Chunhao Cao, Zhenchao Tang, Xingchen Li, Jianmin Guo, Xinxin Chen, Fang Wang, Dongyi He, Jie Li, Yu Du, Bing He, Jianhua Yao, Aiping Lu, Chao Liang   +14 more
wiley   +1 more source

Erosive vulvar lichen planus improved with topical ruxolitinib: A case report

SAGE Open Medical Case Reports
Lichen planus is a chronic immune-mediated inflammatory disorder, and vulvar lichen planus (VLP) is a debilitating subtype often refractory to standard therapy.
Rahila Shaikh, Carly Kirshen
doaj   +1 more source

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis

Nature Communications, 2022
Sarcoidosis is a heterogenous disorder often treated with glucocorticoids. Here the authors show, in an open label, non-randomized, single arm clinical trial involving 10 patients, that treatment with tofacitinib, a Janus kinase inhibitor, is associated ...
William Damsky, Alice Wang, Daniel J. Kim, Bryan D. Young, Katelyn Singh, Michael J. Murphy, Joseph Daccache, Abigale Clark, Ruveyda Ayasun, Changwan Ryu, Meaghan K. McGeary, Ian D. Odell, Ramesh Fazzone-Chettiar, Darko Pucar, Robert Homer, Mridu Gulati, Edward J. Miller, Marcus Bosenberg, Richard A. Flavell, Brett King   +19 more
doaj   +1 more source

PCAF regulates the stability of the transcriptional regulator and cyclin-dependent kinase inhibitor p27Kip1 [PDF]

, 2012
P27(Kip1) (p27) is a member of the Cip/Kip family of cyclin-dependent kinase inhibitors. Recently, a new function of p27 as transcriptional regulator has been reported.
Perearnau Garcia, Anna, Bachs Valldeneu, Oriol, Martínez-Balbás, Marian, Pérez-Luna, Maria, Serratosa i Serdà, Joan, Aguasca, M., Bachs, Oriol, Serratosa, Joan, Martínez Balbás, Marian, Aguasca i Marsà, Marta, Pujol Sobrevía, María Jesús, Pujol, María Jesús, Perearnau, Anna   +12 more
core   +1 more source

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

Advanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li, Yu Zhang, Yu Chen, Lingyun He, Xian Shen, Weijian Sun, Hongbo Zhang   +6 more
wiley   +1 more source

Sarbecoviruses Suppress Innate Immunity by Recruiting PPM1A to Modulate STAT2 and ORF9b Phosphorylation

Advanced Science, EarlyView.
Sarbecovirus ORF9b recruits host phosphatase PPM1A to suppress innate immunity through dual mechanisms. PPM1A directly dephosphorylates ORF9b to sustain its activity and indirectly downregulates STAT2 phosphorylation to impair interferon signaling. Pharmacological inhibition of PPM1A restores antiviral responses and limits sarbecovirus replication ...
Lixiang Xie, Ziye Huang, Zhiyuan Zhang, Yiqiang Zhu, Xiaoqing Liu, Lei Wang, Tongyu Bi, Taizhen Liang, Jintao Lai, Meilin Hu, Guochang Qiu, Shiqi Xiao, Sen Liu, Yaoming Liu, Haiyue Rao, Tao Chen, Haojie Peng, Bin Zhang, Jia Tang, Qianying Li, Yaxin Li, Yuxin Hou, Weibo Yang, Hewei Jiang, Xiancai Ma   +24 more
wiley   +1 more source

Negative patch test findings after initiation of upadacitinib: A case report

SAGE Open Medical Case Reports
Upadacitinib is a systemic Janus kinase inhibitor currently approved for the treatment of atopic dermatitis. Many patients with atopic dermatitis have a concomitant diagnosis of allergic contact dermatitis.
Meghan L McPhie, Melanie D Pratt, Mark G Kirchhof   +2 more
doaj   +1 more source

Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells

Tumor Biology, 2017
Chronic myeloid leukemia is characterized by the presence of the reciprocal translocation t(9;22) and the BCR/ABL oncogene. The BCR/ABL oncogene activates multiple signaling pathways and involves the dysregulation of oncogenes during the progression of ...
Jia-Hua Zhang, Yan-Li He, Rui Zhu, Wen Du, Jun-Hua Xiao   +4 more
doaj   +1 more source

Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor

Molecules, 2021
The purpose of this work is to investigate the protein kinase inhibitory activity of constituents from Acacia auriculiformis stem bark. Column chromatography and NMR spectroscopy were used to purify and characterize betulin from an ethyl acetate soluble ...
Augustine A. Ahmadu, Claire Delehouzé, Anas Haruna, Lukman Mustapha, Bilqis A. Lawal, Aniefiok Udobre, Blandine Baratte, Camilla Triscornia, Axelle Autret, Thomas Robert, Jeannette Chloë Bulinski, Morgane Rousselot, Mélanie Simoes Eugénio, Marie-Thérèse Dimanche-Boitrel, Jacobus P. Petzer, Lesetja J. Legoabe, Stéphane Bach   +16 more
doaj   +1 more source